Integrin expression inhibitor
The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.
1. A method for treating or improving a disease against which an integrin expression inhibition is effective, wherein said disease is at least one selected from the group consisting of arterial sclerosis and retinal angiogenesis, said method comprising:
administering a pharmacologically effective amount of an integrin expression inhibitor of a sulfonamide compound represented by formula (I a ), a pharmacologically acceptable salt thereof or a hydrate thereof, to a patient in need thereof for treating or improving said disease:
wherein in formula (I a ):
the A a ring represents a monocyclic or bicyclic aromatic ring optionally having a substituent;
the B a ring represents an optionally substituted 6-membered cyclic unsaturated hydrocarbon or unsaturated 6-membered heterocycle containing one nitrogen atom as a heteroatom;
the C a ring represents an optionally substituted 5-membered heterocycle containing 1 or 2 nitrogen atoms;
R la represents a hydrogen atom or a C 1 -C 6 alkyl group;
W a represents a single bond or —CH═CH—;
Y a represents a carbon atom or nitrogen atom; and
Z a represents a nitrogen atom or —N(R 2a )—, wherein R 2a is a hydrogen atom or a lower alkyl group.
2. The method of claim 1 , wherein the ring of formula (I a ) formed by the B a ring and C a ring is a N-substituted indole, quinoline or isoquinoline.
3. The method of claim 1 , wherein said sulfonamide compound is N-(3-cyano-4-methyl-1H-indole-7-yl)-3-cyanobenzene-sulfonamide or N-(5-bromo-3-chloro-1H -indole-7-yl)-6-amino-3-pyridinesulfonamide.
4. The method of claim 1 , wherein said disease is a disease against which an antiangiogenic effect is effective.